We narrowed to 8 results for: tac

1. pAAV-flex-taCasp3-TEVp (AAV5)

   Viral Prep

   #45580-AAV5

   Purpose

   Ready-to-use AAV5 particles produced from pAAV-flex-taCasp3-TEVp (#45580). In addition to the viral particles, you will also receive purified pAAV-flex-taCasp3-TEVp plasmid DNA. EF1a-driven, Cre-dependent, bicicstronic expression of designer pro-taCasp3 and TEVp. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Jim Wells, Nirao Shah

   Article

   Yang et al Cell. 2013 May 9;153(4):896-909. doi: 10

   Promoter

   EF1a

   Tags

   None

   Available since

   Sept. 25, 2020

   Availability

   Academic Institutions and Nonprofits only

2. pAAV_hSyn1-SIO-stGtACR1-FusionRed (AAV5)

   Viral Prep

   #105678-AAV5

   Purpose

   Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR1-FusionRed (#105678). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR1-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ofer Yizhar

   Article

   Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

   Promoter

   Syn

   Tags

   FusionRed (Cre-dependent)

   Available since

   Sept. 24, 2020

   Availability

   Academic Institutions and Nonprofits only

3. pAAV_hSyn1-SIO-stGtACR2-FusionRed (AAV1)

   Viral Prep

   #105677-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ofer Yizhar

   Article

   Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

   Promoter

   Syn

   Tags

   FusionRed (Cre-dependent)

   Available since

   Aug. 17, 2018

   Availability

   Academic Institutions and Nonprofits only

4. pAAV-CKIIa-stGtACR2-FusionRed (AAV1)

   Viral Prep

   #105669-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ofer Yizhar

   Article

   Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

   Promoter

   CaMKII

   Tags

   FusionRed

   Available since

   July 17, 2018

   Availability

   Academic Institutions and Nonprofits only

5. pAAV_hSyn1-SIO-stGtACR2-FusionRed (AAV5)

   Viral Prep

   #105677-AAV5

   Purpose

   Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ofer Yizhar

   Article

   Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

   Promoter

   Syn

   Tags

   FusionRed (Cre-dependent)

   Available since

   Oct. 21, 2024

   Availability

   Academic Institutions and Nonprofits only

6. pAAV_hSyn1-SIO-stGtACR2-FusionRed (AAV Retrograde)

   Viral Prep

   #105677-AAVrg

   Purpose

   Ready-to-use AAV Retrograde particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ofer Yizhar

   Article

   Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

   Promoter

   Syn

   Tags

   FusionRed (Cre-dependent)

   Available since

   July 8, 2020

   Availability

   Academic Institutions and Nonprofits only

7. pAAV-CKIIa-stGtACR2-FusionRed (AAV Retrograde)

   Viral Prep

   #105669-AAVrg

   Purpose

   Ready-to-use AAV Retrograde particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ofer Yizhar

   Article

   Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

   Promoter

   CaMKII

   Tags

   FusionRed

   Available since

   July 8, 2020

   Availability

   Academic Institutions and Nonprofits only

8. pAAV-CAG-DIO-NLS-mRuby3-IRES-eGtACR1-ST (AAV9)

   Viral Prep

   #109048-AAV9

   Purpose

   Ready-to-use AAV9 particles produced from pAAV-CAG-DIO-NLS-mRuby3-IRES-eGtACR1-ST (#109048). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-NLS-mRuby3-IRES-eGtACR1-ST plasmid DNA. Cre-dependent expression of the anion channelrhodopsin GtACR1 fused to ER export signal and targeted to the neuronal soma and proximal dendrites, translated from an internal ribosomal entry site (IRES) following mRuby3 expression. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Hillel Adesnik

   Article

   Mardinly et al Nat Neurosci. 2018 Apr 30. pii: 10.1038/

   Promoter

   CAG

   Tags

   mRuby3

   Available since

   Feb. 5, 2024

   Availability

   Academic Institutions and Nonprofits only